Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (36)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bertini, M.
Right arrow Articles by Resegotti, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bertini, M.
Right arrow Articles by Resegotti, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 2:733-737, 1991
© 1991 European Society for Medical Oncology

research-article

Original article: Stage II large B-cell lymphoma with sclerosis treated with MACOP-B

M. Bertini1,, L. Orsucci1, U. Vitolo1, A. Levis1, G. Todeschini2, V. Meneghini2, D. Novero3, C. Tarella4, E. Gallo4, G. Luxi5, M. Pizzuti6, A. Novarino7, A. Urgesi8 and L. Resegotti1

1Divisione di Ematologia Ospedale Molinette Torino
2Cattedra di Ematologia Uniwrsità Verona
3Istituto di Anatomia Patologica Universitd Torino
4Cattedra di Ematologia Unversità Torino
5Divisione di Ematologia Ospedale Busmco Cagliari
6Divisione di Ematologia Ospedale S. Carlo Potenza
7Clinica Medica Università Torino
8Cattedra di Radiologia Università Torino, Italy

Correspondence to: Marilena Bertini, M.D. Divisione di Ematologia Ospedale Molinette, USSL TO VIII, c. Bramante 90, 10126 Torino, Italy

In a series of 193 patients with advanced stage diffuse large-cell lymphoma (DLCL) treated with MACOP-B, 18 (11%) were defined as having a stage II large B-cell lymphoma with sclerosis of the mediastinum. This type of lymphoma has been reported to have a highly aggressive behaviour and special histological and clinical features. In our series young women were more commonly affected and the most striking clinical feature was the presence of a bulky mediastinal mass in 81%. A comparison was made between stage II patients with DLCL with and without sclerosis. The group of patients with sclerosis had prognostic parameters significantly worse than those of the patients without sclerosis, namely, elevated LDH level and bulky disease. The complete remission rates (89% vs 76%) were similar in the two groups and, with a median follow-up of 23 months, survival and disease-free survival rates were also superimposable. MACOP-B chemotherapy has been proven effective in this subgroup of lymphoma patients with sclerosis that had thus far been reported to have a poor prognosis.

DLCL with sclerosis, MACOP-B chemotherapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 haematolHome page
P. L. Zinzani, M. Martelli, V. Poletti, U. Vitolo, P. G. Gobbi, T. Chisesi, G. Barosi, A. J.M. Ferreri, M. Marchetti, N. Pimpinelli, et al.
Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation
Haematologica, September 1, 2008; 93(9): 1364 - 1371.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. van Besien, M. Kelta, and P. Bahaguna
Primary Mediastinal B-Cell Lymphoma: A Review of Pathology and Management
J. Clin. Oncol., March 15, 2001; 19(6): 1855 - 1864.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. L. Zinzani, M. Martelli, M. Magagnoli, E. Pescarmona, L. Scaramucci, F. Palombi, M. Bendandi, M. P. Martelli, S. Ascani, G. F. Orcioni, et al.
Treatment and Clinical Management of Primary Mediastinal Large B-Cell Lymphoma With Sclerosis: MACOP-B Regimen and Mediastinal Radiotherapy Monitored by 67Gallium Scan in 50 Patients
Blood, November 15, 1999; 94(10): 3289 - 3293.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. C. Bishop, W. H. Wilson, D. Pearson, J. Janik, E. S. Jaffe, and P. C. Elwood
CNS Involvement in Primary Mediastinal Large B-Cell Lymphoma
J. Clin. Oncol., August 1, 1999; 17(8): 2479 - 2479.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. A. Abou-Elella, D. D. Weisenburger, J. M. Vose, J. P. Kollath, J. C. Lynch, M. A. Bast, P. J. Bierman, T. C. Greiner, W. C. Chan, and J. O. Armitage
Primary Mediastinal Large B-Cell Lymphoma: A Clinicopathologic Study of 43 Patients From the Nebraska Lymphoma Study Group
J. Clin. Oncol., March 1, 1999; 17(3): 784 - 784.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.